The Energy and Commerce Committee recently passed HR 4439-The Creating Hope Act, reauthorizing a proven voucher program for rare pediatric diseases.
Please put this in the Continuing Resolution package, otherwise it will expire at the end of September.
This successful program has created a pathway for small biotechs and even larger pharmaceutical companies to develop much needed drugs for pediatric rare diseases.
Since 2012 when the program originated, 24 rare pediatric disease drugs have been approved and the number of rare pediatric disease drugs that were in the drug development pipeline in 2019 was a 200% increase over 2016.
At no cost to taxpayers, The Creating Hope voucher program has created over $1 billion in incentives that improve the risk/return ratio of biotech and pharmaceutical companies making them more interested in pediatric rare disease drug development. When a company gets approval for a specific pediatric cancer or rare disease drug they receive a voucher from the FDA, which is transferable and it entitles the holder to put another drug through the FDA’s priority review process allowing them to get the drug to market much faster.
We must act quickly and add the Creating Hope Act to the CR to provide needed time to reauthorize this valuable program to improve much needed rare pediatric drug development.